Open AccessEffect of trimetazidine in experimental animals with coronary heart disease or and in combination with diabetes mellitus
Author(s) -
A Suma Preethi,
C Uthira Kumar,
Y V Ramakrishna Reddy,
K Kalyan Kumar,
B. Nageshwar Rao
Publication year - 2022
Publication title -
international journal of clinical biochemistry and research
Language(s) - English
Resource type - Journals
eISSN - 2394-6377
pISSN - 2394-6369
DOI - 10.18231/j.ijcbr.2022.004
Subject(s) - trimetazidine , diabetes mellitus , blood sugar , streptozotocin , urine , medicine , coronary heart disease , disease , blood lipids , glycosuria , cardiology , heart disease , physiology , endocrinology , cholesterol
The epidemic of cardiovascular disease especially coronary heart disease (CHD) is emerging in rural India and accelerating in urban India. Coronary heart disease is the leading cause of death in India; diabetes accounts for a significant burden of CHD events. Trimetazidine (TMZ) is a piperazine derivative with anti-ischaemic properties. It is the first in a new class of metabolic agent, available for clinical use. : To determine the effect of TMZ on blood parameters in normal, hyperlipidemic, diabetic and Streptozotocin induced diabetic hyperlipidemic rats. Adult male albino rats of Wistar strain, weighing approximately 150 to 180 g, were used in the present study. After various treatments, blood was collected from the rats by sinocular puncture for the blood parameters like Fasting blood glucose, urine sugar, HbA1c and Haemoglobin with standard protocols. The levels of blood glucose, HbA1c and urine sugar were found to be elevated in the entire diseased control group than normal control. TMZ has the potential effect against the STZ induced syndromes with an optimum dose of 40 mg/kg in rats.